Published

Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Frontiers in pharmacology
Date: 2021-01-01
Source: PubMed
DOI: 10.3389/fphar.2021.640241
PubMed: 33716753

Authors

Higgins GA Carroll NK Brown M MacMillan C Silenieks LB Thevarkunnel S Izhakova J Magomedova L DeLannoy I Sellers EM

Watch author

Derived topics and classifications

psilocybin psilocin Depression Microdosing Animal Study Animal Study

Citation graph

0 referenced DOIs found in stored source metadata. 8 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats2026-10-01 Revealing shortcomings in the assessment of psilocybin effects on OCD-related symptoms in preclinical and clinical studies: A systematic review2026-07-01 Psilocybin Decreases Preference for Large Rewards Accompanied by Increased Activity of Parvalbumin Neurons With Perineuronal Nets in the Medial Prefrontal Cortex2026-06-01 Behavioural investigations of psilocybin in non-human animals 1962-2021: A scoping review2026-03-09 Development of a PBPK model of psilocybin/psilocin from Psilocybe cubensis (magic mushroom) in mice, rats, and humans2025-04-21 In vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin2024-01-08 Effects of ketamine optical isomers, psilocybin, psilocin and norpsilocin on time estimation and cognition in rats2022-06-01 Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property.2021-01-01

Related papers

Psilocybin Versus Ketamine - Fast Acting Antidepressant Strategies in Treatment-resistant DepressionClinicalTrials.gov · 2022-05-20 Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of LifeClinicalTrials.gov · 2025-11-25 Psilocybin and Depression - Assessing the Long-term Effects of a Single Administration of Psilocybin on the Psychiatric Symptoms and Brain Activity of Patients With Severe DepressionClinicalTrials.gov · 2017-12-21 Acute Analgesic Effects of DMT on Experimentally Induced Acute Nociceptive Pain, Hyperalgesia and Allodynia in Healthy ParticipantsClinicalTrials.gov · 2026-04-02 Investigation of Psychedelic Effects in Psychoactive SubstancesClinicalTrials.gov · 2026-02-23 Psilocybin vs Ketamine for Alcohol Use DisorderClinicalTrials.gov · 2025-11-28 Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use DisorderClinicalTrials.gov · 2025-11-17